Brain-training and brainpower

Placebo effect largely ignored in psychological intervention studies

 

CHAMPAIGN, Ill., USA (July 9, 2013) — Many brain-training companies tout the scientific backing of their products – the laboratory studies that reveal how their programs improve your brainpower. But according to a new report, most intervention studies like these have a critical flaw: They do not adequately account for the placebo effect. The new analysis appears in the journal Perspectives on Psychological Science.

 

The results of psychological interventions, like medical ones, must be compared to improvements in a control condition, said University of Illinois psychology professor Daniel Simons, who co-wrote the article with Walter Boot, Cary Stothart and Cassie Stutts, of Florida State University. In a clinical trial for a new drug, some participants receive a pill with the critical ingredients, and others receive an identical-looking pill that is inert – a placebo. Because participants cannot tell which they received, people in each condition should be equally likely to expect improvements.

 

In contrast, for most psychology interventions, participants know what’s in their "pill," Simons said.

 

"It’s not possible to use a brain-training program for 10 hours without knowing the type of training you received," he said. "People can form expectations for what will improve based on their experiences with the training tasks, and the existence of differences in expectations between people in treatment and control groups potentially undermines any claim that improvements were due to the treatment itself. Not one of the studies cited by the brain-training companies looks at differing expectations between the groups."

 

Merely having an "active control group," one that does something for the same amount of time as the treatment group, does not protect against the placebo effect, Simons said. A treatment group that completes an intensive memory-training regimen might expect improved performance on other cognitive tasks assessing memory. A control group that does crossword puzzles or watches DVDs for the same amount of time likely won’t expect the same amount of improvement on the same tasks, he said.

 

"These problems are not limited to brain-training studies," Simons said. "They hold true for almost all intervention studies."

 

To illustrate the pervasiveness of this problem, the researchers examined expectations for improvement in studies of the effect of playing action video games on measures of perception and attention.

 

"Such studies find greater improvements in performance on attention and perception tasks after training with action video games than after training with non-action games for the same amount of time," Boot said. "However, even with this sort of active control condition, these interventions still are at risk for differential placebo effects."

 

The researchers measured expectations in two survey studies involving 200 participants each. Participants watched either a short video of an action game ("Unreal Tournament") or one of the games commonly used as controls in these studies ("Tetris" or "The Sims"). They then read descriptions of the cognitive tests used in the studies, watched short videos of the tests, and answered questions about whether they thought their performance on the tests would improve as a result of training on the video game they had viewed.

 

The results showed that expectations for improvement were greater for the action-game group than for the control games on exactly the same tests that showed bigger improvements for action-game training in the intervention studies. In fact, the pattern of expected improvements exactly matched actual improvements seen in video game intervention studies, the researchers found.

 

"If expectations for improvement align perfectly with the actual improvements, then any claim that the treatment was effective is premature," Simons said. "Researchers must first eliminate differences in expectations across conditions."

 

"Even though participants in psychology interventions typically know the nature of their intervention – you can’t play a video game without knowing the game you’re playing – there are steps researchers can take to ensure that the advantages of the treatment group are not due to expectations," Boot said.

 

For example, researchers can mislead participants as to the expected benefits of a particular intervention, giving those in the control group higher expectations for improvement than those in the treatment group. Researchers also can assess expectations generated by treatments in a separate sample of participants to ensure that expectations do not differ between intervention and control treatments.

 

"Although placebo effects can be helpful as well, we need to know what causes improvements in an intervention," Simons said. "We don’t want to recommend new therapies, change school curricula, or encourage the elderly to buy brain-training games if the benefits are just due to expectations for improvement. Only by using better active controls that equate for expectations can we draw definitive conclusions about the effectiveness of any intervention."

 

 

Simons is an affiliate of the Beckman Institute for Advanced Science and Technology at Illinois.

 

Editor’s notes: To reach Walter Boot, call 850-645-8734; email boot@psy.fsu.edu

 

The paper, "The Pervasive Problem with Placebos in Psychology: Why Active Control Groups are Not Sufficient to Rule out Placebo Effects," is available from the U. of I. News Bureau.

 


 

University of Illinois at Urbana-Champaign, 09.05.2013 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…